From Yahoo Finance: 2025-05-26 10:49:00

UBS analyst AJ Rice reaffirmed a “Buy” rating on Cigna Group (CI) with a $390 price target. The company highlighted its strategic departure from Medicare Advantage business at an investor event, showing confidence in its commercial healthcare, pharmacy benefit management, and specialty care services mix.

Rice expressed confidence in Cigna’s ability to achieve low-double-digit earnings growth by moving away from government-related healthcare programs. The company’s diverse business portfolio was emphasized as a strength, with a focus on the GLP1 program to make treatments more accessible and cost-effective for clients and patients.

Cigna Group operates globally through Cigna Healthcare and Evernorth Health Services divisions, with sales capabilities in over 30 markets. While CI holds potential as an investment, some AI stocks may offer greater returns. Check out a report on a promising AI stock with 100x upside potential for comparison.

Read more: UBS Maintains Buy Rating on Cigna (CI) Stock